Thermodynamic analysis does not allow discrimination of agonists and antagonists at human CCK2S-receptors

European Journal of Pharmacology

Volumn 581, Issue 1-2, 2008, Pages 1-12

  Harper, Elaine A ^a   Mitchell, Elizabeth A ^a   Griffin, Eric P ^a   Kalindjian, S Barrett ^a  

^a James Black Foundation   (United Kingdom)

Author keywords

3H JB93182; CCK2S receptors; Thermodynamics

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; BETA ADRENERGIC RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; JB 93242; JB 95008; PENTAGASTRIN; RADIOLIGAND; RL 365260; SL 365260; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG ACTIVITY; DRUG STRUCTURE; ENTHALPY; ENTROPY; INCUBATION TEMPERATURE; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPERATURE SENSITIVITY; THERMODYNAMICS;

ANIMALS; HUMANS; INDOLES; MICE; NIH 3T3 CELLS; RECEPTOR, CHOLECYSTOKININ B; TEMPERATURE; THERMODYNAMICS; TRITIUM;

EID: 38549136726     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.055     Document Type: Article

References (65)

1. Befort K., Tabbara L., Kling D., Maigret B., and Kieffer B.L. Role of aromatic transmembrane residues of the δ-opioid receptor in ligand recognition. J. Biol. Chem. 271 (1996) 10161-10168
2. Beinborn M., Quinn S.M., and Kopin A.S. Minor modification of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties. J. Biol. Chem. 273 (1998) 14146-14151
3. Blaker M., Ren Y., Gordon M.C., Hsu J.E., Beinborn M., and Kopin A.S. Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists. Mol. Pharmacol. 54 (1998) 857-863
4. Blaker M., Ren Y., Seshadri L., McBride E.W., Beinborn M., and Kopin A.S. CCK-B/gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides. Mol. Pharmacol. 53 (2000) 399-406
5. 2A adenosine receptors. Life Sci. 59 (1996) 1373-1388
6. 3 binding discriminates agonistic from antagonistic behaviour. Eur. J. Pharmacol. 298 (1996) 329-334
7. Borea P.A., Varani K., Gessi S., Gilli P., and Gilli G. Binding thermodynamics at the human neuronal nicotine receptor. Biochem. Pharmacol. 55 (1998) 1189-1197
8. Borea P.A., Varani K., Gessi S., Merighi S., Dalpiaz A., Gilli P., and Gilli G. Receptor binding thermodynamics at the neuronal nicotinic receptor. Curr. Top. Med. Chem. 4 (2004) 361-368
9. Chartuvedi K., Shahrestanifar M., and Howells R.D. Mu opioid receptor: role for the amino terminus as a determinant of ligand binding affinity. Mol. Brain Res. 76 (2000) 64-72
10. 50 of an enzymic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
11. 1A receptor ligands. Eur. J. Pharmacol. 312 (1996) 107-114
12. 1 receptor ligands. Life Sci. 67 (2000) 1517-1524
13. B receptor. Eur. J. Pharmacol. 268 (1994) 29-41
14. Detjen K., Yule D., Tseng M.J., Williams J.A., and Logsdon C.D. CCK-B receptors produce similar signals but have opposite growth effects in CHO and Swiss 3T3 cells. Am. J. Physiol. 273 (1997) C1449-C1457
15. Dixon R.A., Sigal I.S., Condelore M.R., Register R.B., Scattergood W., Rands E., and Strader C.D. Structural features required for ligand binding to the beta-adrenergic receptor. EMBO J. 6 (1987) 3269-3275
16. Dufresne M., Seva C., and Fourmy D. Cholecystokinin and gastrin receptors. Physiol. Rev. 86 (2006) 805-847
17. Foucaud M., Tikhonova I.G., Langer I., Escrieut C., Dufresne M., Seva C., Maigret B., and Fourmy D. Partial agonism, neutral antagonism and inverse agonism at the human wild-type and constitutively active cholecystokinin-2 receptors. Mol. Pharmacol. 69 (2006) 680-690
18. Foucaud M., Archer-Lahlou E., Marco E., Tikhonova I.G., Maigret B., Escreieut C., Langer L., and Fourmy D. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin. Regul. Pept. (2007) 10.1016/j.regpep. 2007.098.024
19. Goldstein A., and Barrett R.W. Ligand dissociation constants from competition binding assays: errors associated with ligand depletion. Mol. Pharmacol. 31 (1987) 603-609
20. b/gastrin receptor radioligand binding assay. 10th Camerino-Noordwijkerhout Symposium, Camerino. Perspect. Receptor Res. (1996) 198P
21. 2-receptors in rat cerebral cortex. Br. J. Pharmacol. 151 (2007) 1352-1367
22. Hellmich M.R., Rui X.L., Hellmich H.L., Fleming R.Y., Evers B.M., and Townsend C.M. Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth. J. Biol. Chem. 275 (2000) 32122-32128
23. Hitzeman R. Thermodynamic aspects of drug-receptor interactions. Trends Pharmacol. Sci. 9 (1988) 408
24. Ito M., Iwata N., Taniguchi T., Murayama T., Chihara K., and Matsui T. Functional characterisation of two cholecystokinin-B/gastrin receptor isoforms: a preferential splice donor site in the human receptor gene. Cell Growth Differentiation 5 (1994) 1127-1135
25. B/gastrin receptors. Bioorg. Med. Chem. Lett. 6 (1996) 1171-1174
26. Kalindjian S.B., Dunstone D.J., Low C.M.R., Pether M.J., Roberts S.P., Tozer M.J., Watt G.F., and Shankley N.P. Nonpeptide cholecystokinin-2 receptor agonists. J. Med. Chem. 44 (2001) 1125-1133
27. Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol. Sci. 24 (2003) 346-354
28. Kent R.S., DeLean A., and Lefkowitz R.J. A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modelling of ligand binding data. Mol. Pharmacol. 17 (1980) 14-23
29. 2 receptors. Mol. Pharmacol. 30 (1986) 226-234
30. Kopin A.S., Lee Y.M., McBride E.W., Miller L.J., Lu M., Lin H.Y., Kolakowski L.F., and Beinborn M. Expression cloning and characterisation of the canine parietal cell gastrin receptor. Proc. Natl. Acad. Sci. (USA) 89 (1992) 3605-3609
31. Kopin A.S., McBride E.W., Gordon M.C., Quinn S.M., and Beinborn M. Inter- and intraspecies polymorphisms in the cholecystokinin-B/gastrin receptor alter drug efficacy. Proc. Natl. Acad. Sci. (USA) 94 (1997) 11043-11048
32. Kopin A.S., McBride E.W., Chen C., Freidinger R.M., Chen D., Zhao C.-M., and Beinborn M. Identification of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation. Proc. Natl. Acad. Sci. (USA) 100 (2003) 5525-5530
33. Lay J.M., Jenkins C., Friis-Hansen L., and Samuelson L.C. Structure and developmental expression of the mouse CCK-B receptor gene. Biochem. Biophys. Res. Commun. 272 (2000) 837-842
34. Lee Y.M., Beinborn M., McBride E.W., Lu M., Kolakowski L.F., and Kopin A.S. The human brain cholecystokinin-B/gastrin receptor. Cloning and characterisation. J. Biol. Chem. 268 (1993) 8164-8168
35. Lefkowitz R.J., Cotecchia S., Samama P., and Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14 (1993) 303-307
36. Li J.-G., Raffa R.B., Cheung P., Tzeng T.-B., and Liu-Chen L.-Y. Apparent thermodynamic parameters of ligand binding to the cloned rat μ-opioid receptor. Eur. J. Pharmacol. 354 (1998) 227-237
37. 1 adenosine receptor induced by G protein coupling and guanine nucleotide states of G proteins. Br. J. Pharmacol. 130 (2000) 595-604
38. Maguire P.A., and Loew G.H. Thermodynamics of ligand binding to the cloned δ-opioid receptor. Eur. J. Pharmacol. 318 (1996) 505-509
39. Maksay G. Thermodynamics of γ-aminobutyric acid type A receptor binding differentiate agonists from antagonists. Mol. Pharmacol. 46 (1994) 386-390
40. 2 receptors coupled to adenylate cyclase/protein kinase A signalling cascade. J. Clin. Endocrinol. Metab. 89 (2004) 1277-1284
41. 3 adenosine receptors. Biochem. Pharmacol. 63 (2002) 157-161
42. Miyake A. A truncated isoform of human CCK-B/gastrin receptor generated by alternative usage of a novel exon. Biochem. Biophys. Res. Commun. 208 (1995) 230-237
43. Monstein H.-J., Nilsson I., Ellnebo-Svedlund K., and Svensson S.P.S. Cloning and characterisation of the 5′-end alternatively spliced human cholecystokinin-B receptor mRNAs. Receptors Channels 6 (1998) 165-177
44. 2 receptors. Br. J. Pharmacol. 140 (2003) 218-224
45. 2 receptor up-regulated using engineered transcription factors. Regul. Pept. 129 (2005) 227-232
46. Motulsky H.J., and Mahan L.C. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 25 (1983) 1-9
47. Nakata H., Matsui T., Ito M., Taniguchi T., Naribayashi Y., Arima N., Nakamura A., Kinoshita Y., Chihara K., Hosoda S., and Chiba T. Cloning and characterisation of gastrin receptor from ECL carcinoid tumor of Mastomys natalensis. Biochem. Biophys. Res. Commun. 187 (1992) 1151-1157
48. Pepin M.C., Yue S.Y., Roberts E., Wahlestedt C., and Walker P. Novel "restoration of function" mutagenesis strategy to identify amino acids of the δ-opioid receptor involved in ligand binding. J. Biol. Chem. 272 (1997) 9620-9627
49. Pisegna J.R., De Weerth A., Huppi K., and Wank S.A. Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localisation. Biochem. Biophys. Res. Commun. 189 (1992) 296-303
50. Podlogar B.L., Poda G.I., Demeter D.A., Zhang S.P., Carson J.R., Neilson L.A., Reitz A.B., and Ferguson D.M. Synthesis and evaluation of 4-(N,N-diarylamino)piperidines with high selectivity to the delta-opioid receptor: a combined 3D-QSAR and ligand docking study. Drug Des. Discov. 17 (2000) 34-50
51. Pommier B., Da Nascimento S., Dumont S., Bellier B., Million E., Garbay C., Roques B.P., and Noble F. The cholecystokininB receptor is coupled to two effector pathways through pertussis toxin-sensitive and -insensitive G proteins. J. Neurochem. 73 (1999) 281-288
52. Porteghese P.P., El Kouhen R., Law P.Y., Loh H.H., and Le Bourdonnec B. Affinity labels as tools for the identification of opioid receptor recognition sites. Il Farmaco 56 (2001) 191-196
53. Raffa R.B., and Porreca F. Thermodynamic analysis of the drug-receptor interaction. Life Sci. 44 (1989) 245
54. Ruiz-Gomez A., Garcia-Calvo M., Vazquez J., Marvizǿn J.C.G., Valdivieso F., and Mayor F. Thermodynamics of agonist and antagonist interaction with the strychnine-sensitive glycine receptor. J. Neurochem. 52 (1989) 1775-1780
55. 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268 (1993) 4625-4636
56. Schmitz F., Schrader H., Otte J., Schmitz H., Stuber E., Herzig K., and Schmidt W.E. Identification of CCK-B/gastrin receptor splice variants in human peripheral blood mononuclear cells. Regul. Pept. 15 (2001) 25-33
57. Shankley N.P., Roberts S.P., Watt G.F., Kotecha A., Hull R.A.D., and Black J.W. Analysis of the complex pharmacology expressed by the CCK-B/gastrin ligand PD134,308 on gastric assays. ASPET Pharmacol. 39 (1997) P65
58. Song I., Brown D.R., Wiltshire R.N., Gantz I., Trent J.M., and Yamada T. The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs. Proc. Natl. Acad. Sci. (USA) 90 (1993) 9085-9089
59. Surratt C.K., Johnson P.S., Moriwaki A., Seidleck B.K., Blaschak C.J., Wang J.B., and Uhl G.R. -μ Opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J. Biol. Chem. 32 (1994) 20548-20553
60. Taniguchi T., Matsui T., Ito M., Murayama T., Tsukamoto T., Katakami Y., Chiba T., and Chihara K. Cholecystokinin-B/gastrin receptor signalling pathway involves tyrosine phosphorylations of p125FAK and p42MAP. Oncogene 9 (1994) 861-867
61. Wank S.A., Pisegna J.R., and De Weerth A. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc. Natl. Acad. Sci. (USA) 89 (1992) 8691-8695
62. Weiland G.A., Minneman K.P., and Molinoff P.B. Fundamental difference between the molecular interactions of agonists and antagonists with the β-adrenergic receptor. Nature 281 (1979) 114
63. Weiss J.M., Morgan P.H., Lutz M.W., and Kenakin T.P. The cubic ternary complex receptor-occupancy model I. Model description. J. Theor. Biol. 178 (1996) 151-167
64. Wells J.W., Birdsall N.J.M., Burgen A.S.V., and Hulme E.C. Competitive binding studies with multiple sites-effects arising from depletion of the free radioligand. Biochem. Biophys. Acta. 632 (1980) 464-469
65. 3H-spiroperidol in rat striatum. Mol. Pharmacol. 23 (1983) 303